Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPRB | P23467 | 1/20 | 0.47 |
| ▸ | ACP1 | P24666 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | CPB1 | P15086 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28833774 | 1.00 | MEN1 (0.60) | MEN1KMT2ACTSSPTPN2PTPN1 | |
| SCHEMBL28833866 | 1.00 | MEN1 (0.60) | MEN1KMT2ACTSSPTPN2PTPN1 | |
| SCHEMBL23297722 | 0.89 | CTSS (0.53) | MEN1KMT2ACTSSSMN1; SMN2NPC1 | |
| SCHEMBL23298071 | 0.89 | CTSS (0.53) | MEN1KMT2ACTSSSMN1; SMN2NPC1 | |
| SCHEMBL23297723 | 0.89 | CTSS (0.53) | MEN1KMT2ACTSSSMN1; SMN2NPC1 | |
| SCHEMBL3559422 | 0.87 | MEN1 (0.61) | MEN1KMT2ACTSSPTPN2PTPN1 | |
| SCHEMBL25897297 | 0.87 | CTSS (0.52) | MEN1KMT2ACTSSSMN1; SMN2NPC1 | |
| SCHEMBL25897307 | 0.87 | CTSS (0.52) | MEN1KMT2ACTSSSMN1; SMN2NPC1 | |
| SCHEMBL16974952 | 0.86 | KMT2A (0.60) | MEN1KMT2ACTSSPTPN2PTPN1 | |
| SCHEMBL3562291 | 0.86 | MEN1 (0.60) | MEN1KMT2ACTSSPTPN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4656201-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. | 2025-06-19 | — | — | US | disclosed |
| CN-115873020-B | RAS inhibitors | 锐新医药公司 | 2025-06-13 | — | — | CN | disclosed |
| US-12252497-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2025-03-18 | — | — | US | disclosed |
| US-20250051306-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-02-13 | — | — | US | disclosed |
| US-20240277796-A1 | METHODS FOR INHIBITING RAS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-08-22 | — | — | US | disclosed |
| US-20240262847-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-08-08 | — | — | US | disclosed |
| EP-4346898-A1 | METHODS FOR INHIBITING RAS | Revolution Medicines, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4334325-A1 | RAS INHIBITORS FOR THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4334324-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20230100838-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-03-30 | — | — | US | disclosed |
| US-20220396589-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2022-12-15 | — | — | US | disclosed |
| WO-2022251292-A1 | METHODS FOR INHIBITING RAS | Revolution Medicines, Inc. (US) | 2022-12-01 | — | — | WO | disclosed |
| WO-2022235866-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022235870-A1 | RAS INHIBITORS FOR THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2022-11-10 | — | — | WO | disclosed |
| EP-4065231-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | Revolution Medicines, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| EP-4054720-A1 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| CN-114980976-A | Covalent RAS inhibitors and uses thereof | 锐新医药公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-114901366-A | RAS inhibitors | 锐新医药公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2022060583-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. (US) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396589-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | MEN1 680/4885KMT2A 3443/4885CTSS 800/4885 |
| US-20230100838-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | KRAS, NRAS, HRAS | MEN1 1775/4885KMT2A 2080/4885CTSS 543/4885 |
| US-20250051306-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | MEN1 815/4885KMT2A 3685/4885CTSS 1023/4885 |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | SOS1, PPM1D, PTPN1 | MEN1 755/4885KMT2A 1017/4885CTSS 3690/4885 |
| US-20240262847-A1 | COVALENT RAS INHIBITORS AND USES THEREOF | KRAS, NRAS, HRAS | MEN1 1775/4885KMT2A 2080/4885CTSS 543/4885 |
| US-12252497-B2 | Ras inhibitors | KRAS, NRAS, HRAS | MEN1 680/4885KMT2A 3443/4885CTSS 800/4885 |
| US-20240277796-A1 | METHODS FOR INHIBITING RAS | KRAS, HRAS, NRAS | MEN1 2581/4885KMT2A 3181/4885CTSS 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.